ARIPO

Three Sixty Solar Receives Positive Review of Technology Patentability

Retrieved on: 
Thursday, January 26, 2023

Brian Roth, CEO of Three Sixty Solar states, “I’m very encouraged by this positive response from ARIPO.

Key Points: 
  • Brian Roth, CEO of Three Sixty Solar states, “I’m very encouraged by this positive response from ARIPO.
  • Three Sixty Solar has received notification from ARIPO that the organization has completed their initial review of the Company’s patent application.
  • According to their review, the four primary claims that differentiate Three Sixty Solar’s technology all pass the three tests for patentability; the claims are novel, inventive, and have industrial applicability.
  • The Company is encouraged that the US PTO and other patent offices will reach the same positive conclusion as ARIPO regarding patentability of the primary claims.

Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

Retrieved on: 
Sunday, November 27, 2022

16/500,504 Methods of preventing or treating Ophthalmic Diseases covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD).

Key Points: 
  • 16/500,504 Methods of preventing or treating Ophthalmic Diseases covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD).
  • 11285155 that protects the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037.
  • Kinarus is currently developing KIN001 as an oral treatment for wet age-related macular degeneration, idiopathic pulmonary fibrosis, and Covid-19.
  • Kinarus possesses the exclusive worldwide license to pamapimod from Roche Pharmaceuticals Ltd. covering all therapeutic indications.

Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

Retrieved on: 
Tuesday, November 22, 2022

16/500,504 Methods of preventing or treating Ophthalmic Diseases covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD).

Key Points: 
  • 16/500,504 Methods of preventing or treating Ophthalmic Diseases covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD).
  • 11285155 that protects the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037.
  • Kinarus is currently developing KIN001 as an oral treatment for wet age-related macular degeneration, idiopathic pulmonary fibrosis, and Covid-19.
  • Kinarus possesses the exclusive worldwide license to pamapimod from Roche Pharmaceuticals Ltd. covering all therapeutic indications.

Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate

Retrieved on: 
Tuesday, April 26, 2022

Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate

Key Points: 
  • Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
    Grant of KIN001 composition of matter patent strengthens proprietary position in U.S. until at least 2037
    Basel, Switzerland, April 26, 2022.
  • Kinarus AG ('Kinarus') announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No.
  • 11285155 entitled "Pharmaceutical Combinations for Treating Cancer" that covers the Kinarus lead therapeutic candidate KIN001.
  • Kinarus' differentiated therapeutic candidate, KIN001, has broad potential in numerous therapeutic areas.